(0)

ViroCyt

ViroCyt, LLC is the leader in the field of rapid virus quantification. Our goal is to provide the tools that deliver meaningful improvements to mission critical processes, such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role. The Company was recently honored with the prestigious “Rising Star” award in recognition of our commitment to improving world health through innovations in virus detection technologies. To see a video of the award ceremony, click here.

IMG_0724

Recent News

up
down
  • ViroCyt Wins Colorado BioScience Association’s “Rising Star” Award

    BOULDER, CO–(Marketwire – November, 2014) - ViroCyt, LLC, the leader in rapid virus quantification, announced today that it has received the “Rising Star” award from the Colorado Bioscience Association after being nominated as one of three companies in the category. “The Colorado BioScience Association’s Rising Star award recognizes early stage growth companies that have made great  Continue Reading »

    Read More arrow
  • ViroCyt and I&L Biosystems Launch Virus Counter® 3100 at the World Vaccine Congress in Brussels

    BOULDER, CO–(Marketwire – October, 2014) - ViroCyt, LLC, the leader in rapid virus quantification, announced today that, in partnership with I&L Biosystems GmbH, it is formally launching the Virus Counter® 3100 in Europe at the World Vaccine Congress to be held October 13-15 in Brussels, Belgium. “The Virus Counter 3100 is the marquee analytical tool for  Continue Reading »

    Read More arrow
  • United States Department of Commerce Partners With ViroCyt to Expand Asian Markets

    BOULDER, CO–(Marketwired – Aug 27, 2014) - ViroCyt, LLC, the leader in rapid virus quantification, announced today that it is working with the US Department of Commerce’s Export Assistance Center In Denver to increase awareness of how the cutting edge Virus Counter system can be used to dramatically accelerate the creation of life-saving products. According to  Continue Reading »

    Read More arrow
  • United States Government-Supported Ebola Research Consortium Utilizes ViroCyt’s Technology for Rapid Virus Quantification

    BOULDER, CO–(Marketwire – August, 2014) - ViroCyt, LLC, the leader in rapid virus quantification, announced today that its breakthrough Virus Counter instrument is being used by a group of laboratories to develop filovirus medical countermeasures.  The Filovirus Animal Nonclinical Group or “FANG” is a US interdepartmental and interagency group established to support and facilitate the creation  Continue Reading »

    Read More arrow
  • ViroCyt Strengthens Management Team

    BOULDER, CO – (Marketwired – June 11, 2014) - ViroCyt, LLC, the leader in rapid virus quantification, announced today that Michael Olszowy, PhD, has joined the team as Chief Technology Officer. Dr. Olszowy is a formally trained cellular and molecular immunologist with 16 years of experience developing and commercializing life science technologies. Most recently, he held  Continue Reading »

    Read More arrow

Upcoming Events


Feb
9

ASM Biodefense & Emerging Diseases Research Meeting Event Details

Mar
3

IMAPAC World Vaccine Summit India Event Details

Apr
7

World Vaccine Congress US Event Details

Apr
25

BIT World Congress of Vaccine China Event Details

May
13

American Society of Gene and Cell Therapy Annual Meeting Event Details